Additionally, CYP1A2 was reported to play a vital role in the gender disparity of HCC by metabolizing 17β-estradiol to generate the potent anti-tumor metabolite 2-methoxy estradiol, which inhibits HCC growth in vitro and in vivo. Here, CYP1A2 is linked to hepatocellular carcinoma.